Receptor Acetylcholine Nicotinic ở Động vật Có Phổi: Từ Cấu Trúc Đến Chức Năng

Physiological Reviews - Tập 89 Số 1 - Trang 73-120 - 2009
Edson X. Albuquerque1, Edna F. R. Pereira2, Manickavasagom Alkondon2, Scott W. Rogers3
1Department of Pharmacology & Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, MD USA
2University of Utah
3NEUROBIOLOGY & ANATOMY

Tóm tắt

Các nghiên cứu cổ điển về nicotine của Langley vào đầu thế kỷ 20 đã giới thiệu khái niệm "chất tiếp nhận", từ đó khái niệm "thụ thể" bắt đầu được hình thành. Các nghiên cứu tiếp theo, được hỗ trợ bởi cơ quan điện Torpedo, một nguồn phong phú của các thụ thể nicotinic loại cơ (nAChRs), và sự phát hiện α-bungarotoxin, một loại độc tố rắn mà gắn kết pseudo-bất hồi phục với nAChR cơ, đã dẫn đến việc nAChR cơ trở thành kênh ion nhạy cảm với thụ thể được mô tả tốt nhất cho đến nay. Với sự phát triển của các nghiên cứu chức năng và di truyền vào cuối những năm 1980, sự tồn tại của nAChRs trong não của động vật có vú đã được xác nhận và nhận thức rằng nhiều loại nAChR đóng góp vào tính chất tâm lý của nicotine và các loại thuốc khác cũng như vào bệnh lý thần kinh của nhiều bệnh, bao gồm Alzheimer, Parkinson và tâm thần phân liệt, đã xuất hiện kể từ đó. Bài đánh giá này cung cấp một cái nhìn tổng quan toàn diện về những phát hiện này và những phát hiện gần đây về tác động của sự đa dạng phong phú trong chức năng và biểu hiện của gia đình thụ thể này đối với các tế bào thần kinh và không phải thần kinh trong toàn bộ cơ thể. Mặc dù có nhiều phát triển này, nhưng hiểu biết của chúng ta về những đóng góp của các loại nAChR thần kinh cụ thể vào nhiều khía cạnh của sinh lý học trong toàn bộ cơ thể vẫn còn ở giai đoạn sơ khai.

Từ khóa

#Nicotinic acetylcholine receptors #ligand-gated ion channels #neuropharmacology #receptor diversity #mammalian brain.

Tài liệu tham khảo

10.1007/s002490050248

10.1016/S0885-3924(02)00374-3

10.1007/s002109900078

10.1523/JNEUROSCI.4985-04.2005

Albuquerque EX, Alkondon M, Pereira EFR, Castro NG, Schrattenholz A, Barbosa CT, Bonfante-Cabarcas R, Aracava Y, Eisenberg HM, Maelicke A.Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function.J Pharmacol Exp Ther280: 1117–1136, 1997.

10.1073/pnas.71.7.2818

10.3109/10799899709036607

10.1111/j.1749-6632.1995.tb17464.x

10.1016/S0166-4328(00)00208-4

10.1016/S0378-4274(98)00309-9

10.1016/0014-2999(90)94190-9

Alkondon M, Albuquerque EX.Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. I. Pharmacological and functional evidence for distinct structural subtypes.J Pharmacol Exp Ther265: 1455–1473, 1993.

10.3109/10799899109064693

10.1152/jn.2001.86.6.3043

10.1016/S0079-6123(03)45007-3

Alkondon M, Albuquerque EX.Nicotinic receptor subtypes in rat hippocampal slices are differentially sensitive to desensitization and early in vivo functional up-regulation by nicotine and to block by bupropion.J Pharmacol Exp Ther313: 740–750, 2005.

10.1152/jn.00708.2001

10.1124/jpet.106.103135

10.1016/S0014-2999(00)00006-6

Alkondon M, Pereira EF, Albuquerque EX.Mapping the location of functional nicotinic and gamma-aminobutyric acidA receptors on hippocampal neurons.J Pharmacol Exp Ther279: 1491–1506, 1996.

10.1523/JNEUROSCI.20-01-00066.2000

10.1016/S0006-8993(98)00880-4

Alkondon M, Aracava Y, Pereira EFR, Albuquerque EX.A single in vivo application of cholinesterase inhibitors has neuron type-specific effects on nicotinic receptor activity in guinea pig hippocampus.J Pharmacol Exp Ther. In press.

10.1152/jn.00214.2003

10.1016/S0028-3908(00)00156-8

Alkondon M, Pereira EFR, Barbosa CT, Albuquerque EX.Neuronal nicotinic acetylcholine receptor activation modulates γ-aminobutyric acid release from CA1 neurons of rat hippocampal slices.J Pharmacol Exp Ther283: 1396–1411, 1997.

10.1111/j.1460-9568.1997.tb01702.x

10.1523/JNEUROSCI.19-07-02693.1999

10.1152/jn.01119.2006

Alkondon M, Pereira EFR, Wonnacott S, Albuquerque EX.Blockade of nicotinic currents in hippocampal neurons defines methyllycaconitine as a potent and specific receptor antagonist.Mol Pharmacol41: 802–808, 1992.

10.1523/JNEUROSCI.5631-03.2004

10.1016/j.bcp.2007.06.023

Alkondon M, Rocha ES, Maelicke A, Albuquerque EX.Diversity of nicotinic acetylcholine receptors in rat brain. V. α-Bungarotoxin-sensitive nicotinic receptors in olfactory bulb neurons and presynaptic modulation of glutamate release.J Pharmacol Exp Ther278: 1460–1471, 1996.

Altavista MC, Gozzo S, Iacopino C, Albanese A.A genetic study of neostriatal cholinergic neurones in C57BL/6 and DBA/2 mice.Funct Neurol2: 273–279, 1987.

10.1002/(SICI)1097-0029(19981001)43:1<29::AID-JEMT5>3.0.CO;2-H

10.1111/j.1476-5381.1995.tb15018.x

10.1038/sj.ijo.0801654

10.1016/0014-5793(87)80192-8

Aracava Y, Ikeda SR, Daly JW, Brookes N, Albuquerque EX.Interactions of bupivacaine with ionic channels of the nicotinic receptor. Analysis of single-channel currents.Mol Pharmacol26: 304–313, 1984.

10.1016/S0028-3908(03)00317-4

10.1113/jphysiol.1961.sp006634

10.1016/j.lfs.2007.01.013

10.1083/jcb.200206096

10.1038/labinvest.3780379

10.1002/(SICI)1096-9861(19960520)369:1<31::AID-CNE3>3.0.CO;2-L

10.1016/S0301-0082(02)00079-5

10.1159/000049362

10.1146/annurev.neuro.30.051606.094345

10.1007/s007020050149

10.1016/0309-1651(77)90016-9

10.1016/j.brainresrev.2004.06.008

10.1074/jbc.M005246200

10.1038/86477

Bennett MR.History of the Synapse. London: Harwood Academic, 2001.

10.1111/j.1471-4159.1988.tb10600.x

Bernard C.Leçons sur Les Effets des Substances Toxiques et Medicamenteuses. Paris: Bailliere, 1857.

10.1007/s00213-006-0418-z

10.12968/bjon.1996.5.19.1195

10.1083/jcb.111.6.2613

10.1523/JNEUROSCI.17-16-06094.1997

10.1016/j.pbb.2007.04.011

10.1038/319368a0

10.1523/JNEUROSCI.05-09-02545.1985

Boulter J, O'Shea-Greenfield A, Duvoisin RM, Connolly JG, Wada E, Jensen A, Gardner PD, Ballivet M, Deneris ES, McKinnon D.α3, α5, β4: three members of the rat neuronal nicotinic acetylcholine receptor-related gene family form a gene cluster.J Biol Chem265: 4472–4482, 1990.

10.1038/sj.emboj.7600620

10.1016/0304-3940(96)12561-1

10.1038/35077011

10.1007/BF02741361

10.1523/JNEUROSCI.3169-05.2005

10.1242/dev.02619

10.1046/j.1471-4159.2003.01640.x

10.1523/JNEUROSCI.21-02-00504.2001

10.1016/S0165-6147(00)01979-9

10.1002/jnr.10465

10.1002/(SICI)1097-4695(199804)35:1<29::AID-NEU3>3.0.CO;2-D

Carlson NG, Wieggel WA, Chen J, Bacchi A, Rogers SW, Gahring LC.Inflammatory cytokines IL-1α, IL-1β, IL-6, TNF-α impart neuroprotection to an excitotoxin through distinct pathways.J Immunol163: 3963–3968, 1999.

10.1016/0304-3940(93)90876-M

10.1016/S0006-3495(95)80213-4

10.1038/nsmb951

10.1016/S0896-6273(04)00115-1

10.1523/JNEUROSCI.23-21-07820.2003

10.1016/S0896-6273(01)00516-5

Changeux JP.Nicotinic Acetylcholine Receptors: From Molecular Biology to Cognition. New York: Odile Jacob, 2003.

10.1017/S0033583500004352

10.1152/jn.2002.87.6.2851

10.1242/jcs.01492

10.1007/BF00966328

10.1038/sj.emboj.7600436

10.1038/378075a0

10.1126/science.1108239

10.1300/J069v10n01_08

10.1038/329204a0

10.1074/jbc.270.9.4424

10.1016/0896-6273(92)90031-8

10.1016/S0014-2999(00)00036-4

10.3109/10409239409086798

10.1074/jbc.274.38.27145

Corey-Bloom J.Galantamine: a review of its use in Alzheimer's disease and vascular dementia.Int J Clin Pract57: 219–223, 2003.

10.1523/JNEUROSCI.18-02-00648.1998

10.1016/S0896-6273(00)80741-2

10.1074/jbc.270.20.11749

10.1016/j.jphysparis.2005.12.012

10.1098/rspb.1963.0058

10.1016/0896-6273(90)90344-F

10.1007/s002130050327

10.1093/geronb/58.5.P249

10.1021/bi011864f

10.1124/mol.64.5.1217

Dale HH.The action of certain esters of choline and their relation to muscarine.J Pharmacol Exp Ther6: 147–190, 1914.

10.1007/s10571-005-3968-4

10.1039/a900728h

10.1016/S0014-2999(00)00579-3

10.1146/annurev.pharmtox.47.120505.105214

10.1038/ni1229

10.1523/JNEUROSCI.10-10-03413.1990

10.1113/jphysiol.1955.sp005297

10.1113/jphysiol.1954.sp005129

Deneris ES, Boulter J, Connolly J, Wada E, Wada K, Goldman D, Swanson LW, Patrick J, Heinemann S.Genes encoding neuronal nicotinic acetylcholine receptors.Clin Chem35: 731–737, 1989.

10.1113/jphysiol.1983.sp014595

10.1126/science.1470919

10.1016/0169-328X(92)90244-6

10.2741/2445

10.1074/jbc.M200066200

10.1002/syn.20051

10.1016/0006-2952(84)90437-4

10.1523/JNEUROSCI.23-17-06740.2003

10.1523/JNEUROSCI.20-01-00133.2000

10.1523/JNEUROSCI.3315-04.2004

10.1002/cne.903210313

10.1023/A:1023692705700

10.1021/bi020586x

10.1016/j.bcp.2006.03.027

10.1016/0896-6273(89)90207-9

10.1152/jn.1999.82.6.3213

Dwoskin LP, Crooks PA.Competitive neuronal nicotinic receptor antagonists: a new direction for drug discovery.J Pharmacol Exp Ther298: 395–402, 2001.

10.1046/j.1460-9568.1998.00095.x

10.1152/jn.1942.5.3.211

10.1152/jn.1941.4.5.362

10.1152/jn.1999.81.2.895

10.1523/JNEUROSCI.19-15-06298.1999

10.1016/S0076-6879(98)93034-8

10.1016/S0079-6468(05)43004-0

10.1016/S0733-8619(18)30104-X

10.1113/jphysiol.1950.sp004492

10.1124/mol.104.000042

Fenster CP, Beckman ML, Parker JC, Sheffield EB, Whitworth TL, Quick MW, Lester RA.Regulation of α4β2 nicotinic receptor desensitization by calcium and protein kinase C.Mol Pharmacol55: 432–443, 1999.

10.1523/JNEUROSCI.19-12-04804.1999

10.1113/jphysiol.1982.sp014393

10.1073/pnas.71.4.1376

10.1523/JNEUROSCI.16-24-07892.1996

Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ.A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is up-regulated by chronic nicotine treatment.Mol Pharmacol41: 31–37, 1992.

10.1523/JNEUROSCI.3597-05.2005

10.1016/S0169-328X(01)00309-6

10.1523/JNEUROSCI.18-20-08228.1998

10.1523/JNEUROSCI.18-04-01187.1998

10.1016/S0891-0618(00)00109-5

10.1002/1096-8628(20010108)105:1<20::AID-AJMG1047>3.0.CO;2-C

10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I

10.1016/0014-2999(93)90468-W

10.1016/S0006-8993(01)02057-1

10.1016/j.jneuroim.2005.05.007

10.1046/j.1471-4159.2003.02074.x

10.1074/jbc.M707330200

10.1002/neu.20106

10.1002/cne.10943

10.1016/j.neurobiolaging.2004.07.005

10.1002/cne.10942

10.1208/aapsj070486

Gahring LC, Rogers SW.Nicotinic acetylcholine receptor expression in the hippocampus of 27 mouse strains reveals novel inhibitory circuitry.Hippocampus.In press.

10.1038/359500a0

10.1074/jbc.M412389200

10.1073/pnas.92.7.2919

10.1111/j.1471-4159.2004.02743.x

10.1016/S0006-8993(97)00793-2

10.1016/S0169-328X(96)00256-2

10.1074/jbc.271.18.10709

Giacobini E.Nicotine acetylcholine receptors in human cortex: aging and Alzheimer's disease. In:Biology of Nicotine, edited by Lippiello PM, Collins AC, Gray AC, Robinson JH. New York: Raven, 1992, p. 183–215.

Giovannini MG, Scali C, Prosperi C, Bellucci A, Pepeu G, Casamenti F.Experimental brain inflammation and neurodegeneration as model of Alzheimer's disease: protective effects of selective COX-2 inhibitors.Int J Immunopathol Pharmacol16: 31–40, 2003.

10.1111/j.1749-6632.1999.tb11331.x

10.1523/JNEUROSCI.21-14-05182.2001

10.1016/S0014-2999(02)01944-1

10.1016/j.tips.2006.02.005

10.1016/0896-6273(88)90081-5

10.1016/j.pneurobio.2004.09.006

10.1124/mol.108.045203

10.1016/j.tips.2006.07.004

Gramsbergen JBP, Hodgkins PS, Rassoulpour A, Turski WA, Guidetti P, Schwarcz R.Brain-specific modulation of kynurenic acid synthesis in the rat.J Neurochem69: 290–298, 1997.

10.1111/j.0906-6705.2006.00410.x

10.1111/1523-1747.ep12325606

10.1038/383713a0

10.1016/0092-8674(93)90294-Z

Green WN, Ross AF, Claudio T.Acetylcholine receptor assembly is stimulated by phosphorylation of its gamma subunit.Neuron191: 659–666, 1991.

10.1074/jbc.272.33.20945

10.1073/pnas.73.7.2424

10.1385/JMN:30:1:63

10.1073/pnas.0509024102

10.1046/j.1471-4159.2000.0740237.x

10.1164/rccm.200309-1270OC

10.1002/glia.20432

10.1002/(SICI)1097-4547(19971101)50:3<457::AID-JNR12>3.0.CO;2-3

10.1046/j.1471-4159.2002.01027.x

10.1192/bjp.162.1.80

Hajek P, Stead LF, West R, Jarvis M.Relapse Prevention Interventions for Smoking Cessation. Cochrane Database Syst Rev CD003999, 2005.

10.1385/JMN:30:1:101

10.1038/sj.emboj.7600828

10.1074/jbc.M402452200

10.1016/j.jmb.2007.03.067

10.1523/JNEUROSCI.14-06-03898.1994

10.1529/biophysj.106.082693

10.1523/JNEUROSCI.21-19-07463.2001

10.1016/0169-328X(95)00068-4

10.1002/(SICI)1097-4547(19990801)57:3<295::AID-JNR1>3.0.CO;2-0

10.1046/j.1460-9568.1998.00208.x

10.1358/dnp.2003.16.5.829313

10.1007/s10254-003-0005-1

10.2174/1389450033490902

Hu M, Whiting Theobald NL, Gardner PD.Nerve growth factor increases the transcriptional activity of the rat neuronal nicotinic acetylcholine receptor beta 4 subunit promoter in transfected PC12 cells.J Neurochem62: 392–395, 1994.

10.1016/j.ejphar.2007.07.037

10.1002/neu.10177

Isaacs JT.The aging ACI/Seg versus Copenhagen male rat as a model system for the study of prostatic carcinogenesis.Cancer Res44: 5785–5796, 1984.

10.1083/jcb.103.1.205

10.1074/jbc.M011549200

10.1152/jn.2000.83.5.2682

10.1523/JNEUROSCI.3009-04.2004

10.1111/j.1469-7793.1997.603bd.x

10.7326/0003-4819-114-10-840

Kang TH, Ryu YH, Kim IB, Oh GT, Chun MH.Comparative study of cholinergic cells in retinas of various mouse strains.Cell Tissue Res317: 109–115, 2004.

Kao PN, Dwork AJ, Kaldany RR, Silver ML, Wideman J, Stein S, Karlin A.Identification of the α subunit half-cystine specifically labeled by an affinity reagent for the acetylcholine receptor binding site.J Biol Chem259: 11662–11665, 1984.

10.1111/j.1749-6632.1986.tb21503.x

Katz B.The Croonian Lecture. The transmission of impulses from nerve to muscle, the subcellular unit of synaptic action.Proc R Soc Lond B155: 455–477, 1961.

Katz B.The Release of Neural Transmitter Substances.Springfield, IL: Thomas, 1969.

10.1113/jphysiol.1957.sp005838

10.1038/nn1956

10.1016/j.lfs.2003.09.037

10.1152/physiolgenomics.00202.2003

10.1016/0006-8993(87)91556-3

10.1016/S0002-9440(10)65199-1

10.1016/j.brainres.2006.01.127

10.1523/JNEUROSCI.23-27-09024.2003

10.1113/jphysiol.2001.013847

10.1016/j.bbrc.2004.10.132

10.1074/jbc.M008035200

10.1016/S0006-8993(98)00138-3

Kiss C, Ceresoli-Borroni G, Guidetti P, Zielke CL, Zielke HR, Schwarcz R.Kynurenate production by cultured human astrocytes.J Neural Transm110: 1–14, 2003.

10.1073/pnas.78.6.3678

10.1046/j.0022-3042.2001.00754.x

Kracun S, Harkness PC, Gibb AJ, Millar NS.Influence of the M3-M4 intracellular domain upon nicotinic acetylcholine receptor assembly, targeting and function.Br J Pharmacol. In press.

10.1016/0306-4522(80)90149-9

10.1113/jphysiol.1981.sp013558

10.1111/j.1460-9568.1995.tb01129.x

Kühne W.On the origin and the causation of vital movement.Proc R Soc Lond B4: 1888.

10.1111/j.1471-4159.2005.03468.x

10.1124/jpet.105.084954

10.1523/JNEUROSCI.17-23-09035.1997

10.1055/s-2007-961816

10.1016/0304-3940(88)90377-1

10.1124/mol.104.006429

10.1038/sj.npp.1300032

10.1113/jphysiol.1905.sp001128

10.1124/mol.105.017459

10.1073/pnas.0407739102

10.1093/nar/27.1.340

10.1016/0306-4522(96)00095-4

Lee CY.Recent advances in chemistry and pharmacology of snake toxins.Adv Cytopharmacol3: 1–16, 1979.

10.1038/nature04156

10.1016/S0278-5846(03)00172-6

10.1523/JNEUROSCI.13-06-02680.1993

10.1128/MCB.21.13.4369-4378.2001

Lester HA, Fonck C, Tapper AR, McKinney S, Damaj MI, Balogh S, Owens J, Wehner JM, Collins AC, Labarca C.Hypersensitive knockin mouse strains identify receptors and pathways for nicotine action.Curr Opin Drug Discov Dev6: 633–639, 2003.

10.1152/jn.1995.74.1.195

10.1016/0896-6273(95)90249-X

10.1523/JNEUROSCI.16-21-06878.1996

10.1007/s002130050667

10.1182/blood-2002-04-1104

10.1007/BF02740634

10.1021/bi00588a003

10.1196/annals.1254.007

10.1073/pnas.081553598

10.1124/jpet.103.065037

10.1007/s00213-007-0967-9

10.1126/science.1134246

10.1523/JNEUROSCI.3953-04.2005

10.1007/BF01738910

10.1016/S0197-4580(98)00088-8

10.1124/jpet.107.123109

10.1016/S0079-6123(08)62470-X

Lukas RJ, Changeux JP, Le Novere N, Albuquerque EX, Balfour DJ, Berg DK, Bertrand D, Chiappinelli VA, Clarke PB, Collins AC, Dani JA, Grady SR, Kellar KJ, Lindstrom JM, Marks MJ, Quik M, Taylor PW, Wonnacott S.International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits.Pharmacol Rev51: 397–401, 1999.

10.1146/annurev.neuro.22.1.443

10.1212/WNL.50.4.986

Macklin KD, Maus AD, Pereira EF, Albuquerque EX, Conti-Fine BM.Human vascular endothelial cells express functional nicotinic acetylcholine receptors.J Pharmacol Exp Ther287: 435–439, 1998.

10.1016/S0079-6123(08)62092-0

10.1073/pnas.0437947100

10.1093/emboj/20.1.47

10.1016/j.bcp.2007.07.034

10.1016/S0896-6273(02)00625-6

10.1002/neu.10148

10.1016/S0896-6273(00)00042-8

Mao D, Perry DC, Yasuda RP, Wolfe BB, Kellar KJ.The α4β2α5 nicotinic cholinergic receptor in rat brain is resistant to up-regulation by nicotine in vivo.J Neurochem104: 446–456, 2008.

10.1046/j.0022-3042.2002.00805.x

10.1016/j.bcp.2007.06.030

Marks MJ, Stitzel JA, Collins AC.Dose-response analysis of nicotine tolerance and receptor changes in two inbred mouse strains.J Pharmacol Exp Ther239: 358–364, 1986.

10.1016/0091-3057(89)90406-1

Marks MJ, Stitzel JA, Collins AC.Time course study of the effects of chronic nicotine infusion on drug response and brain receptors.J Pharmacol Exp Ther235: 619–628, 1985.

10.1073/pnas.75.9.4329

10.1016/0005-2736(81)90516-2

Martin-Ruiz CM, Court JA, Molnar E, Lee M, Gotti C, Mamalaki A, Tsouloufis T, Tzartos S, Ballard C, Perry RH, Perry EK.α4 but not α3 and α7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease.J Neurochem73: 1635–1640, 1999.

10.1113/jphysiol.1955.sp005397

10.1016/S0006-8993(98)00558-7

10.1124/mol.54.5.779

10.1017/S1041610205003017

10.1007/s00213-005-0076-6

10.1126/science.7569895

McGrath J, McDonald J, Macdonald J.Transdermal Nicotine for Induction of Remission in Ulcerative Colitis. Cochrane Database Syst Rev CD004722, 2004.

10.1146/annurev.biochem.68.1.59

10.1016/0306-4522(94)90187-2

10.1523/JNEUROSCI.19-08-02887.1999

10.1074/jbc.M010735200

10.1523/JNEUROSCI.09-02-00507.1989

10.1016/S0006-8993(00)02863-8

10.1016/S0006-8993(00)02533-6

10.1113/jphysiol.1980.sp013504

10.1124/jpet.301.2.494

10.1111/j.0906-6705.2004.00274.x

10.1006/dbio.1996.0253

10.1073/pnas.0505090102

10.1124/jpet.302.1.197

Moliver M.Computerization helps reduce human error in patient dosing.Contemp Longterm Care10: 56–58, 1987.

10.1016/S0378-5955(00)00124-6

10.1016/0014-2999(92)90158-Z

10.1016/0304-3940(88)90285-6

10.1523/JNEUROSCI.1228-08.2008

10.1016/j.neuroscience.2005.09.008

10.1523/JNEUROSCI.10-01-00169.1990

10.1016/0896-6273(92)90115-T

10.1523/JNEUROSCI.11-08-02588.1991

10.1016/S0306-4522(01)00460-2

10.1046/j.1471-4159.2001.00602.x

Nastuk WL.Membrane potential changes at a single muscle end-plate produced by transitory application of acetylcholine with an electrically controlled microjet.Federation Proc12: 102, 1953.

10.1124/mol.63.2.332

10.2165/00002512-199711030-00005

10.1016/j.febslet.2004.08.035

10.1038/299793a0

10.1038/302528a0

10.1016/S0166-4328(00)00204-7

Nordberg A.Pharmacological treatment of cognitive dysfunction in dementia disorders.Acta Neurol Scand Suppl168: 87–92, 1996.

Nordberg A.Toward an early diagnosis and treatment of Alzheimer's disease.Int Psychogeriatr15: 223–237, 2003.

10.1016/0006-291X(89)90805-X

Numa S.Molecular basis for the function of ionic channels.Biochem Soc Symp52: 119–143, 1986.

10.1097/WNR.0b013e328010a1ff

10.1111/j.1432-1033.1991.tb16231.x

10.1146/annurev.ecolsys.33.010802.150424

10.1523/JNEUROSCI.17-23-09165.1997

10.1097/00001756-200507130-00018

10.1016/j.jneuroim.2007.10.029

10.1152/ajpcell.00422.2002

10.1124/jpet.103.049981

10.1016/S0014-2999(00)00396-4

10.1002/syn.10121

10.1002/syn.20249

10.1074/jbc.274.26.18335

10.1016/0304-3940(96)12889-5

10.1111/j.1460-9568.2007.05636.x

10.1124/mol.65.3.611

10.1016/S0166-2236(97)01205-8

10.1083/jcb.113.6.1371

10.1042/BST0341037

Peng X, Gerzanich V, Anand R, Whiting PJ, Lindstrom J.Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover.Mol Pharmacol46: 523–530, 1994.

Pereira EF, Alkondon M, McIntosh JM, Albuquerque EX.α-Conotoxin-ImI: a competitive antagonist at alpha-bungarotoxin-sensitive neuronal nicotinic receptors in hippocampal neurons.J Pharmacol Exp Ther278: 1472–1483, 1996.

Pereira EF, Reinhardt-Maelicke S, Schrattenholz A, Maelicke A, Albuquerque EX.Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons.J Pharmacol Exp Ther265: 1474–1491, 1993.

Pereira EFR, Alkondon M, Reinhardt S, Maelicke A, Peng X, Lindstrom J, Whiting P, Albuquerque EX.Physostigmine and galanthamine: probes for a novel binding site on the α4β2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells.J Pharmacol Exp Ther270: 768–778, 1994.

10.1002/neu.10146

Pereira EFR, Reinhardt-Maelicke S, Schrattenholz A, Maelicke A, Albuquerque EX.Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons.J Pharmacol Exp Ther265: 1474–1491, 1993.

Perry DC, Davila-Garcia MI, Stockmeier CA, Kellar KJ.Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies.J Pharmacol Exp Ther289: 1545–1552, 1999.

10.1016/S0014-2999(00)00064-9

10.1002/jcc.20084

10.1523/JNEUROSCI.21-01-j0003.2001

10.1002/neu.10102

10.1042/bst0250824

10.1038/37120

10.1101/lm.70004

10.1002/jnr.20216

10.1152/physrev.1984.64.4.1162

10.1158/1055-9965.EPI-05-0983

10.1016/j.tins.2004.06.008

10.1016/j.bcp.2007.06.015

Quik M, McIntosh JM.Striatal α6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy.J Pharmacol Exp Ther316: 481–489, 2006.

Quik M, Philie J, Choremis J.Modulation of α7 nicotinic receptor-mediated calcium influx by nicotinic agonists.Mol Pharmacol51: 499–506, 1997.

10.1038/380347a0

Ramoa AS, Alkondon M, Aracava Y, Irons J, Lunt GG, Deshpande SS, Wonnacott S, Aronstam RS, Albuquerque EX.The anticonvulsant MK-801 interacts with peripheral and central nicotinic acetylcholine receptor ion channels.J Pharmacol Exp Ther254: 71–82, 1990.

10.1038/sj.npp.1300583

10.1111/j.1471-4159.2005.03134.x

10.1523/JNEUROSCI.1079-05.2005

10.1023/A:1022534019718

10.1523/JNEUROSCI.3353-07.2007

10.1016/1074-5521(95)90103-5

10.1523/JNEUROSCI.18-13-04825.1998

10.1523/JNEUROSCI.12-12-04611.1992

10.1002/neu.10112

10.1016/j.cell.2006.03.042

10.1016/j.neuropharm.2005.01.030

10.1097/00042737-200012080-00004

10.1016/j.neuropharm.2007.08.017

10.1074/jbc.M308260200

10.1124/mol.65.6.1526

10.1124/jpet.102.045773

Samochocki M, Zerlin M, Jostock R, Groot Kormelink PJ, Luyten WH, Albuquerque EX, Maelicke A.Galantamine is an allosterically potentiating ligand of the human α4/β2 nAChR.Acta Neurol Scand Suppl176: 68–73, 2000.

10.1016/0006-8993(91)91211-I

10.1006/jsbi.1997.3950

10.1124/mol.61.5.1222

10.1016/j.expneurol.2005.07.004

10.1016/S0006-291X(86)80263-7

10.1002/1098-2396(20001215)38:4<375::AID-SYN2>3.0.CO;2-Y

10.3109/10799899309073669

Schrattenholz A, Pereira EF, Roth U, Weber KH, Albuquerque EX, Maelicke A.Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands.Mol Pharmacol49: 1–6, 1996.

Schroder B, Reinhardt-Maelicke S, Schrattenholz A, McLane KE, Kretschmer A, Conti-Tronconi BM, Maelicke A.Monoclonal antibodies FK1 and WF6 define two neighboring ligand binding sites on Torpedo acetylcholine receptor α-polypeptide.J Biol Chem269: 10407–10416, 1994.

10.1016/0197-4580(91)90107-U

10.1016/j.biopsych.2006.04.006

10.1007/978-1-4615-4709-9_17

10.1124/jpet.102.034439

10.1016/S0006-3223(01)01078-2

10.1111/j.1471-4159.1985.tb04005.x

10.1093/schbul/16.2.185

10.1523/JNEUROSCI.13-02-00596.1993

10.1016/S0306-4522(96)00425-3

10.1073/pnas.071540198

10.1002/neu.10114

10.1016/j.schres.2006.03.037

Shaw KP, Aracava Y, Akaike A, Daly JW, Rickett DL, Albuquerque EX.The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex.Mol Pharmacol28: 527–538, 1985.

Sherby SM, Eldefrawi AT, Albuquerque EX, Eldefrawi ME.Comparison of the actions of carbamate anticholinesterases on the nicotinic acetylcholine receptor.Mol Pharmacol27: 343–348, 1985.

10.1093/carcin/18.8.1595

10.1038/nature04708

10.1192/bjp.185.6.452

Slemmer JE, Martin BR, Damaj MI.Bupropion is a nicotinic antagonist.J Pharmacol Exp Ther295: 321–327, 2000.

10.1385/JMN:30:1:9

Smith MM, Lindstrom J, Merlie JP.Formation of the α-bungarotoxin binding site and assembly of the nicotinic acetylcholine receptor subunits occur in the endoplasmic reticulum.J Biol Chem262: 4367–4376, 1987.

10.1146/annurev.biochem.69.1.145

Snaedal J, Johannesson T, Jonsson JE, Gylfadottir G.The effects of nicotine in dermal plaster on cognitive functions in patients with Alzheimer's disease.Dementia7: 47–52, 1996.

Sobel A, Hofler J, Heidmann T, Changeux JP.Structural and functional properties of the acetylcholine regulator.Adv Cytopharmacol3: 191–196, 1979.

10.1016/0028-3908(95)00122-M

10.1523/JNEUROSCI.0027-07.2007

10.1016/S0304-3835(97)00455-2

10.1124/mol.107.036939

10.1038/nrc1648

10.1016/j.brainres.2006.05.093

10.2527/2003.8151237x

10.1016/S0166-4328(97)00207-6

10.1053/eujp.2001.0319

10.1016/S0014-2999(01)01182-7

10.1016/S0014-2999(99)00886-9

10.1016/0922-4106(95)00080-1

10.1002/glia.10154

10.1002/cncr.22963

10.1111/j.1469-7793.2000.00515.x

10.1254/jjp.82.85

Sumikawa K, Gehle VM.Assembly of mutant subunits of the nicotinic acetylcholine receptor lacking the conserved disulfide loop structure.J Biol Chem267: 6286–6290, 1992.

10.1002/jnr.20850

10.1523/JNEUROSCI.07-10-03334.1987

10.1016/S0169-328X(99)00302-2

10.1113/jphysiol.1963.sp007137

10.1124/mol.54.1.59

10.1126/science.1099420

10.1097/01.JGP.0000196628.12010.35

10.1002/glia.10132

10.1101/lm.43602

10.1111/j.1469-7793.2000.00021.x

10.1038/ncpgasthep0316

10.1016/S0006-3495(98)77783-5

10.1016/0006-8993(93)90065-U

10.1111/j.1471-4159.1992.tb10037.x

10.1016/j.biocel.2004.07.009

10.1523/JNEUROSCI.2112-05.2005

10.1111/j.1471-4159.1989.tb09218.x

10.1016/0006-8993(88)90815-3

10.1073/pnas.0507889103

10.1006/jsbi.1997.3949

10.1016/j.jmb.2004.12.031

10.1523/JNEUROSCI.5240-04.2005

10.1016/S0014-2999(01)01139-6

10.1016/0896-6273(92)90114-S

10.1038/nrn1722

10.1002/cne.902840212

10.1016/S0361-9230(97)00003-8

10.1074/jbc.M703432200

10.1016/j.neuron.2005.05.005

10.1196/annals.1254.009

10.1074/jbc.M705369200

10.1074/jbc.M501813200

10.1074/jbc.271.30.17656

10.1038/nature01339

10.1074/jbc.275.8.5626

10.1016/j.jns.2004.11.050

10.1124/mol.60.6.1201

10.1101/SQB.1996.061.01.039

10.1016/j.neuroscience.2004.07.016

10.1016/S0024-3205(03)00083-3

Whiteaker P, Sharples CG, Wonnacott S.Agonist-induced up-regulation of α4β2 nicotinic acetylcholine receptors in M10 cells: pharmacological and spatial definition.Mol Pharmacol53: 950–962, 1998.

10.1001/jama.298.22.2654

10.1038/35069076

10.1016/0006-8993(95)01046-8

10.1016/0014-5793(89)80514-9

10.1016/0165-6147(90)90242-Z

10.1016/S0166-2236(96)10073-4

10.3109/15563659609013830

10.1523/JNEUROSCI.23-08-03176.2003

10.1111/j.1749-6632.1993.tb23029.x

10.1074/jbc.M400335200

10.1016/j.bmcl.2003.09.105

10.1124/jpet.104.066787

10.1523/JNEUROSCI.0840-06.2006

10.1128/MCB.00456-06

10.1016/0024-3205(86)90057-3

10.1016/0896-6273(93)90192-T

10.1523/JNEUROSCI.17-16-06122.1997

10.1124/jpet.107.128751

10.1111/j.1469-7793.1998.667bm.x

10.1128/MCB.24.16.6919-6930.2004

10.1016/j.gene.2005.09.034

10.1016/j.expneurol.2004.12.015

10.1016/S0378-4274(01)00502-1

10.1152/jn.00769.2003

10.1124/mol.104.000299

10.1016/S0896-6273(00)80253-6

10.1113/jphysiol.1990.sp017974

10.1523/JNEUROSCI.23-27-09004.2003

10.1523/JNEUROSCI.2807-05.2006

Zia S, Ndoye A, Nguyen VT, Grando SA.Nicotine enhances expression of the α3, α4, α5, α7 nicotinic receptors modulating calcium metabolism and regulating adhesion and motility of respiratory epithelial cells.Res Commun Mol Pathol Pharmacol97: 243–262, 1997.

10.1523/JNEUROSCI.18-12-04461.1998

10.1093/emboj/18.5.1235

Zorumski CF, Thio LL, Isenberg KE, Clifford DB.Nicotinic acetylcholine currents in cultured postnatal rat hippocampal neurons.Mol Pharmacol41: 931–936, 1992.

10.1016/j.ejphar.2006.03.077

10.1111/j.1749-6632.1999.tb11339.x

10.1124/mol.52.5.886